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Context: A not negligible part of hypothyroid patients on levothyroxine therapy do not 
normalize serum thyrotropin (TSH) concentrations. “Refractory hypothyroidism,” i.e., a con­
dition characterized by persistently abnormal serum TSH levels despite adequate titration 
of l­T4 substitution therapy, requires biochemical and instrumental investigation, but no 
definite etiology is found in up to 15% of cases.
objective: To report patients presenting with refractory hypothyroidism with proven 
improper storage of levothyroxine tablets.
Design: Patients on l­T4 substitution therapy referred to three Italian outpatient Clinics 
of Endocrinology between January 2013 and December 2015 for refractory hypothy­
roidism were investigated for levothyroxine tablet exposure to humidity, light, and high 
temperature.
Results: We report eight patients, accounting for approximately 1% of all hypothyroid 
patients and 5% of those with refractory hypothyroidism in our series. Careful anamnesis 
disclosed that these patients stored levothyroxine tablets inappropriately. Normalization 
of serum TSH concentrations was obtained in all cases by simply recommending to 
store the new levothyroxine tablets away from heat, light, and humidity.
Conclusion: Refractory hypothyroidism linked to improper storage of l­T4 tablets does 
exist and might be an underrecognized entity. In addition to proper modalities of ingestion 
of l­T4 tablets, patients need to be instructed on proper modalities of storage, as well.
Keywords: levothyroxine, improper storage, replacement therapy, refractory hypothyroidism, environment
INtRoDUCtIoN
Hypothyroidism is a common disorder, with a prevalence of approximately 5% and an incidence of 
approximately 250/100,000 per year in the adult population, but both prevalence and incidence keep 
rising (1, 2). Consequently, levothyroxine (l-T4) is one of the most prescribed medications. In the 
United States, l-T4 ranked first in the year 2014 list of top medicines by prescription, because 120 
million prescriptions were dispensed (3). This represents a steady 4% annual increment compared 
with 103, 105, 112, and 117 million in the years 2010, 2011, 2012, and 2013, respectively. In The 
Netherlands, the prescriptions of l-T4 rose steadily from approximately 305,000 in the year 2005 
to 465,000 in 2011 (4). In the United Kingdom, the number of prescriptions has doubled from 
approximately 7 million in the year 1998 to 19 million in the year 2007 (5). Thus, it is likely that 
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l-T4 prescriptions will increase further worldwide. Even though 
novel formulations (soft gel capsules, oral solution) have been 
launched into the marketplace, yet they are not available in all 
countries (6), and thus the classic formulation of l-T4 for oral 
use is the tablet.
Replacement therapy of hypothyroidism, which is prescribed 
by both specialists and general practitioners (7), is monitored 
by measuring serum thyrotropin (TSH) to ensure it reaches 
target levels (normalization). Except for the pregnancy setting, 
the recommended upper limit for serum TSH concentrations is 
4.12 mU/L (7), though elderly persons tend to have greater serum 
levels (2). Based on a recent survey among endocrinologists from 
all continents, of whom approximately 900 responded, almost 
100% of respondents request serum TSH assay to monitor sub-
stitutive l-T4 therapy (8). However, 60% of endocrinologists also 
request serum-free thyroxine, 8% request free triiodothyronine, 
and 8% request total triiodothyronine. Once the first serum TSH 
check is performed (mostly between 4 and 8 weeks after initiation 
of therapy), rechecks are performed every 6 months by half of 
the respondents, but every 3  months or less by approximately 
10% of the respondents (8). Approximately 15–20% of patients 
taking l-T4 show persistently abnormal serum TSH levels 
(a condition called “refractory hypothyroidism”), and this prob-
lem is frequently addressed by increasing the daily dose of l-T4 
(9, 10), with associated frequent requests of the above hormone 
assays. Ultimately, a thorough diagnostic work-up is necessary to 
disclose the cause of the problem (9). However, in approximately 
15% of such patients, a cause cannot be found (9).
Recent guidelines recommend that “l-thyroxine should be 
stored per product insert at 20–25°C (68–77°F) and protected from 
light and moisture” (7). Nevertheless, except for the above review 
article (9), other reviews (11), guidelines (12), or major textbooks 
(13) do not mention inappropriate storage among the causes of 
increased requirement of l-thyroxine. Thus, improper storage 
remains an overlooked cause. Also, no case reports have appeared 
to support the above recommendation until the description of 
grossly improper storage by one of us (14). For this hypothyroid 
woman, there were multiple factors of improper storage of the T4 
tablets. Tablets were removed from the blister, transferred in a 
transparent vial, and exposed directly to the humidity originating 
from a humidifier, to the sunlight, and to the high temperature 
originating from closeness of the tablets to the bedroom heating 
unit (14). After the patient was instructed to remove all these 
factors for new l-T4 tablets, serum TSH became entirely normal.
The observation of the above patient (14) underscores the 
importance of careful history taking as the first step in the 
management of patients with refractory hypothyroidism (9). 
Particularly, careful history taking should start with detailed 
information on modalities of l-T4 tablet storage, the timing of 
l-T4 ingestion with respect to the timing and type of meals, the 
liquids used to swallow the tablet, and the use of other drugs/
dietary supplements. Upon publication of such case report (14), 
Salvatore Benvenga was alerted by the coauthors of the present 
article that they have observed similar cases of elevation of serum 
TSH, the cause of which could only be improper storage of l-T4 
tablets. Indeed, in all these patients, proper storage of new tablets 
was ensued by normalization of serum TSH.
These patients and the additional patients observed by 
Salvatore Benvenga are reported here.
BaCKGRoUND
patients and Methods
Between January 2013 and December 2015, we have observed 
eight patients with refractory hypothyroidism in whom, upon 
careful anamnesis, we suspected improper storage of their l-T4 
tablets. Four patients live in Southern Italy (Messina, Sicily), 
two in Central Italy (Pisa, Tuscany), and two in Northern Italy 
(Modena, Emilia-Romagna).
Prior to our observation, these eight patients had been man-
aged by their general practitioner, endocrinologist, or both. Based 
on the experience gained with the patient described previously 
(14), a careful anamnesis was carried out, starting from a detailed 
interview on the modalities of storage of the l-T4 tablets. Indeed, 
in the checklist of the 15 items to take care of in history taking and 
physical examination of patients with refractory hypothyroidism, 
the first is to inquire carefully about storage of l-T4 (9). The only 
abnormality that surfaced at anamnesis in the eight patients was 
an improper storage of l-T4 tables. Improper storage consisted in 
taking the l-T4 tablets away from their packages and/or exposing 
them to heating sources, light and humidity. In all eight patients, 
we also wished to check the expiration date of the l-T4 tablets 
that patients were taking, this typically being 18  months from 
manufacturing. In all cases, the tablets were not expired and were 
still valid for at least 8 months. Because we were confident that 
inappropriate storage was the cause of persistent TSH elevation, 
we immediately suggested proper storage for new packages of 
l-T4 tablets from the same brand in the same pharmacy, and 
no changes in the l-T4 daily dose were done to patients. Indeed, 
we advised the patients to eliminate the l-T4 tablets exposed to 
heat, light, and/or humidity sources, to take new l-T4 packages 
from the pharmacy, and to keep new l-T4 tablets within their 
packages—away from the above cited sources—until the intake 
time. A thorough diagnostic work-up (9) was planned, should 
this measure have failed upon the first TSH check 2 months after 
the beginning of therapy with properly stored new l-T4 tablets.
Three patients observed by Salvatore Benvenga were available 
for a temperature check of the microenvironment associated with 
improper storage and the microenvironment associated with proper 
storage in months representative of the four seasons, using a digital 
thermometer. External and internal temperatures in the three 
homes were taken with the same digital thermometer, which was 
provided by Salvatore Benvenga. No home had air conditioning.
statistics
Continuous data are given as mean ±  SD and median, while 
categorical data as percentage. The statistical significance of the 
difference in serum TSH under the proper storage conditions 
versus the improper storage conditions was analyzed by the 
Mann–Whitney test (difference between serum levels) or by 
the exact Fisher’s text (difference between percentages of target 
levels). For microenvironment temperatures, the corresponding 
differences between storages were tested by the one-way analysis 
of variance (ANOVA).
taBLe 1 | Details on changes in thyroid function tests prior to and during l­T4 therapy, with associated daily dosage of l­T4, under conditions of improper l­T4 storage 
(i.e., before our observation) or proper l­T4 storage (after our observation and recommendations) in the eight patients with refractory hypothyroidism.a
Before and at our observation after our observation
Case no.,  
age and sex
L-t4 daily dose  
[μg/kg bw/day]
Ft4  
(pg/ml)
tsH  
(mU/L)
action taken at our observation l-t4 daily dose  
[μg/kg bw/day]
tsH  
(mU/L)
Ft4  
(pg/ml)
1, 45 years  
female
Pretherapy 7.9 19.6
100 μg/day [1.47] 9.5 9.5–10.8 l­T4 dose increased to 125 µg [1.84 µg/kg bw/day]
125 μg/day [1.84] 8.6 l­T4 dose increased to 150 µg [2.20 µg/kg bw/day] 150 μg/day [2.20] 0.51
150 μg/day [2.20] 5.7 Get a new l­T4 package and store it in a drawer of the  
wardrobe closet, located in a room with no heating units
100 μg/day [1.47] 2.2 11.6
2, 65 years  
female
Pretherapy 8.1 16.2
75 μg/day [1.41] 9.2 7.3–9.4 Get a new l­T4 package and store in a wardrobe in the  
bedroom (almost 3 meters away for the heating unit)
75 μg/day [1.41] 3.0–4.2 10.9
3, 56 years  
female
Pretherapy 7.7 25.8
100 μg/day [1.39] 8.9 10.9 l­T4 dose increased to 125 µg [1.74 µg/kg bw/day]
125 μg/day [1.74] 7.6 150 µg [2.08 µg/kg bw/day] 150 μg/day [2.08] 0.06
150 μg/day [2.08] 4.7 Get a new l­T4 package and store in a drawer of the nightstand,  
unexposed to sunlight and located about 1.5 meters from  
the heating unit
100 μg/day [1.39] 1.8 13.3
4, 71 years  
female
Pretherapy N.A. 2.6 l­T4 dose maintained
75 μg/day [1.44] 1.0–2.6 Get a new l­T4 package and store it in a drawer of the  
bedroom commode (located about 3 m from the heating unit).
75 μg/day [1.44] 2.8; 3.0 N.A.
3.6, 5.9
5, 43 years  
female
Pretherapy 7.3 27.1 l­T4 dose increased to 100 µg [1.92 µg/kg bw/day] 100 μg/day [1.92] 2.7 12.4
75 μg/day [1.44] 10.7 9.7–16.8 Get a new l­T4 package and locate it into a drawer of another  
closet in a room with no heating units
100 µg [1.92] 9.0
6, 52 years  
female
Pretherapy 6.9 42.3 l­T4 dose increased to 175 µg [2.03 µg/kg bw/day] 175 μg/day [2.03] 3.0 13.3
125 μg/day [1.45] 12.0 23.7 Get a new l­T4 package and store it into a drawer of a small room  
communicating with the kitchen room, but far away from burners  
and heating unit
175 μg/day [2.03] 7.4
7, 78 years  
male
Pretherapy 7.6 15 l­T4 dose increased to 100 µg [1.4 µg/kg bw/day] 100 µg [1.4] 5.9 9.4
75 μg/day [1.0] 7.1 13–21 Get a new l­T4 package and store it in the drawer  
of the nightstand
100 µg [1.4] 9.5
8, 70 years  
female
Pretherapy 8.8 8 Leave the tablet in the package, and remove it immediately  
before taking it
125 μg/day [1.90] 2.7–4.3 N.A.
7.3 1.4
125 μg/day [1.90] 11.5 125 μg/day [1.90]
tsH (mU/L) tsH (mU/L)
Statistics (vs after our observation)b
m ± SD 10.16 ± 4.87 P = 3.9 × 10−7 2.87 ± 1.83
median 9.45 3.0
>4.12 21/22 
measurements 
(95.4%)
P < 0.0001 (OR = 98) 3/17 measurements (17.7%)
bw, body weight; FT4, free thyroxine; l-T4, levothyroxine; m, mean; N.A., not available; OR, odds ratio; TSH, thyrotropin.
aDetails on improper and proper modalities of storage. In each of the eight patients, TSH levels above 4.12 mU/L are typed boldface.
bBy Wilcoxon test (m ± SD) or Fisher’s exact test (percentages). FT4 reference values are 8.2–18.4 pg/ml for patient nos. 1–4; 8.0–17.0 pg/ml for patient nos. 5 and 6; 7–15 pg/ml 
for patient nos. 7 and 8.
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We considered a P value lower than 0.05 as statistically signifi-
cant, and a P value comprised between 0.10 and 0.5 as borderline 
significant.
Results
Data are summarized in Table 1.
All patients were adult or elderly, and all but one were 
women. Seven patients were affected by the goitrous variant of 
Hashimoto’s thyroiditis. The diagnosis of Hashimoto’s thyroiditis 
was based on elevated antithyroid (ab anti-thyroglobulin and/or 
anti-thyroperoxidase) autoantibodies and diffusely hypoechoic 
aspect of the thyroid gland on ultrasound in all cases. One 
patient (case 4) had previously undergone total thyroidectomy 
due to a large multinodular goiter with compressive symptoms. 
The improper storage consisted in exposure of the l-T4 tablets 
to heating (case nos. 2, 5, 6), humidity (no. 3), both heating 
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and humidity (no. 1), light (no. 7), or both light and heating 
(no. 4, 8).
In particular, our patients used to store l-T4 tablets as follows:
– Patient 1 in a drug cabinet of water closet, above the heating 
unit, about 40 cm from both the shower and Jacuzzi; patient 
2 in a drawer of the kitchen room, around 20 cm from the 
burners and owen; patient 3 in a water closet where mold 
originating from the roof and balcony was evident; patient 
4 (previously undergone thyroidectomy for euthyroid benign 
multinodular goiter) in a transparent glass placed on the 
nightstand, under both the night light and the abat jour, since 
6:00 p.m. until 8:00 a.m.; patient 5 in a drug cabinet of the 
water closet, above the heating unit; patient 6 in a drawer of 
the kitchen room, around 40 cm from the burners and owen; 
patient 7 in a transparent glass placed in the kitchen room, 
close to the window, since 2:00 p.m. until 6:00 a.m.; patient 
8 in a transparent glass placed on the nightstand, close to the 
heating unit and the light from a night bulb, since 11:00 p.m. 
until 8:00 a.m.
Improper storage was associated with greater levels of serum 
TSH and, almost always, with the policy of the family physician 
and/or endocrinologist to deal with this problem by increasing 
the daily dose of l-T4. During this time of improper storage, 
a greater number of TSH assays were requested to monitor 
therapy. In brief, upon correctly storing the tablets, TSH levels 
were fourfold lower (P < 0.001), and more frequently on target. 
It should be noted that the proper storage-associated TSH levels 
of 4.2 mU/L (for the 65-year-old case no. 2), 4.3 mU/L (for the 
70-year-old case no. 8), and 5.9 mU/L (for the 78-year-old case 
no. 7) correspond to the upper normal limit of 4.33 mU/L for 
the 60–69 year-old reference population, and 5.9 mU/L for the 
70–79 year-old reference population (7.50 mU/L for the at least 
80-year-old reference population) based on the NHANES III 
study (2). Finally, if increased prior to our observation, the daily 
dose of l-T4 could be decreased under proper storage conditions.
As mentioned under Section “Patients and methods,” three 
patients were available for a temperature check of the micro-
environment associated with improper storage and the 
micro environment associated with proper storage in months 
representative of the four seasons (Table 2). Temperatures very 
close to or above 25°C were measured under conditions of 
improper storage. Similar temperatures were observed only in 
summer months under conditions of proper storage. With regard 
to pertinent weather conditions of the years 2013–2015 for three 
cities where patients continue to live, the annual relative humidity 
was 64% (Messina), 72.8% (Pisa), and 78.7% (Modena), with an 
average of 247  days (Messina) to 352  days of relative humid-
ity ≥ 60% (Modena). Messina was the warmest city, with an aver-
age annual temperature of 19.6°C (maximum 22.6°C, minimum 
15.9°C), and 94 days of values ≥ 25°C (maximum temperature, 
144 days; minimum temperature, 31 days). Like most of Sicily, 
Messina features an annual average of 300 days and 2700 hours 
of sunshine compared with an average of 2000 hours in the rest 
of Italy (15), particularly around 2150  hours in Modena and 
around 2300 hours in Pisa (16, 17). In sum, Salvatore Benvenga 
observed twice more cases than either coauthor probably because 
the weather conditions of Messina mimic the environmental 
conditions of improper storage better than either Pisa or Modena.
DIsCUssIoN
Wrong storage of medications at patients’ homes is not rare. 
Based on an interview of persons living in 49 homes, half of them 
kept medications in the bedroom or kitchen (18). Moreover, light, 
temperature and moisture sensitivity is not a thyroid hormone-
restricted characteristic (19).
To our knowledge, only one study (reported in abstract 
form) tested different formulations of l-T4 for their resistance 
to heat (20). Two novel formulations of l-T4, namely, the soft 
gel capsule and oral solution, were compared with the classic 
tablet formulation. The soft gel capsule is a gelatine shield pearl 
containing l-T4, which is solubilized in glycerol. Oral solution 
is l-T4 contained in predosed ampoules, with l-T4 solubilized 
in glycerol and ethanol. The tested l-T4 tablets were of three 
types: lactose-free but with calcium phosphate; lactose-free, 
calcium phosphate-free but containing colloidal silicon; lactose-
containing. This challenge consisted in keeping each of the five 
formulations in an incubator at the constant temperature of 
25°C for 6 months. At 0, 3, and 6 months, T4 was extracted and 
measured by variable wavelength detector— high-performance 
liquid chromatography (HPLC). At the end of the 6 months, the 
two novel formulations ranked better than tablets.
Approximately 15–20% of patients receiving l-T4 have high 
serum TSH levels, even when their dose is increased, a condition 
referred to as “refractory hypothyroidism” that prompts endocrine 
consultation (9, 10). As detailed in the Section “Introduction,” 
the issue of improper storage of l-T4 is poorly known. This 
issue of improper storage is reminiscent of that pertaining to the 
improper ingestion of l-T4 tablets soon after food intake (most 
frequently at breakfast) or using coffee as a swallowing liquid or 
having coffee soon after swallowing the l-T4 tablets with water. 
The publication of papers reporting patients with refractory 
hypothyroidism caused by inappropriate intake of l-T4 tablets 
(21, 22) was of help to both patients and physicians, who have 
become more aware of such entity (7).
As suspected, the patient reported previously (14) was the 
classic tip of the iceberg. Together with the eight patients reported 
here, there are now nine cases described in the literature with 
refractory hypothyroidism that is likely attributable to inappro-
priate storage of the l-T4 tablets and consequent degradation of 
the hormone. In the same 3-year interval of time during which 
the eight patients came to observation (2013–2015), the authors 
of the present paper observed a total of approximately 1,500 (or 
500 per year) new hypothyroid patients under l-T4 therapy. 
Twelve percent of these 1,500 patients (180 or 60 patients per 
year) have refractory hypothyroidism caused by pseudomal-
absorption or true malabsorption (e.g., celiac disease, protonic 
pump-inhibitors, etc.) (9). Hence, in the series reported here, 
improper storage accounts for approximately 4.5% (8/180) of 
all cases of refractory hypothyroidism. Also, improper storage 
would occur at a frequency of approximately 1% (8/1500) of 
hypothyroid patients taking l-T4 tablet. While we acknowledge 
that our frequency cannot be universally representative, some 
taBLe 2 | Temperatures taken at the indicated places in three of the eight patients, all three from Messina, under conditions associated with improper storage (in italics) 
or proper storage.a
patient no. 1 patient no. 2 patient no. 4
External temperature (balcony or window)
08:00; 16:00; 21:00 17.2; 25.3; 19.5°C (May) 11.7; 14.5; 12.8°C (March) 15.5; 18.7; 15.8 (April)
08:00; 16:00; 21:00 25.4; 32.6; 29.4°C (July) 25.7; 32.2; 29.3°C (August) 24.7; 31.1; 28.5 (August)
08:00; 16:00; 21:00 20.8; 25.2; 19.5°C (October) 18.1; 22.6; 18.9°C (November) 18.8; 23.4; 19.6 (October)
08:00; 16:00; 21:00 10.7; 15.3; 13.1°C (January) 9.2; 12.7; 10.4°C (February) 11.2; 15.3; 13.0 (January)
Internal temperature, Improper storage Heating unit Off, Heating Unit On Burners and Owen Off, Burners and  
Owen On
Nightstand lights Off or On
Spring (21:00 in pts 1 and 2; 06:00 in pt 4) 24.1°C; N/A (May) 23.5; 25.3°C (March) 18.4; 27.1°C (April)
Summer (21:00 in pts 1 and 2; 06:00 in pt 4) 30.7°C; N/A (July) 29.6; 31.8°C (August) 28.0; 38.6°C (August)
Fall (21:00 in pts 1 and 2; 06:00 in pt 4) 20.6°C; N/A (October) 23.1; 26.7°C (November) 22.2; 30.8°C (October)
Winter (21:00 in pts 1 and 2; 06:00 in pt 4)c 15.4°C; 25.3°C (January) 22.9; 25.5°C (February) 22.4; 30.3°C (January)
Mean ± SD [median] 22.7 ± 6.4 [22.3] vs 25.3 (n = 1) 24.8 ± 3.2 [23.3] vs 27.3 ± 3.0 [26.1] 22.7 ± 3.9 [22.3] vs 31.7 ± 4.9 [30.5]
Statistics (Off vs On) Not done P = 0.29 P = 0.029
Internal temperature, Proper storageb Heating unit Off Heating Unit On Burners and Owen Off Burners and  
Owen On
Nightstand lights Off or On
Spring (21:00 in pts 1 and 2; 06:00 in pt 4) 22.3°C; N/A (May) 22.0; 22.1°C (March) 17.7; 20.8°C (April)
Summer (21:00 in pts 1 and 2; 06:00 in pt 4) 29.1°C; N/A (July) 29.4; 29.4°C (August) 27.1; 30.2°C (August)
Fall (21:00 in pts 1 and 2; 06:00 in pt 4) 20.0°C; N/A (October) 19.6; 19.6°C (November) 19.3; 21.5°C (October)
Winter (21:00 in pts 1 and 2; 06:00 in pt 4)c 13.8°C; 22.4°C (January) 21.7; 21.8°C (February) 21.6; 22.9°C (January)
Mean ± SD [median] 21.3 ± 6.1 [21.1]; 22.4 (n = 1) 23.2 ± 4.3 [21.8]; 23.2 ± 4.3 [21.9] 21.4 ± 4.1 [20.4]; 23.8 ± 4.3 [22.2]
Statistics (Off vs On) Not done P = 0.99 P = 0.44
Statistics (Off vs Off) Improper vs Proper P = 0.77 P = 0.57 P = 0.66
Statistics (On vs On) Improper vs Proper Not done P = 0.17 P = 0.05
aTemperatures ≥ 25.0°C are typed boldface. In patient no. 2, internal temperatures were always taken just before starting to cook or just after ending to cook for dinner. Statistical 
differences between temperatures tested by one-way analysis of variance (ANOVA).
N/A, not applicable.
bThe closet of patient no. 1 had no heating unit, while the wardrobe in the bedroom of patient no. 2 or the commode in the bedroom of patient no. 4 were located 2.8 or 3.3 m from 
the heating unit. For patient no. 1, under conditions of proper storage of the l-T4 tablets, heating unit on refers to the nearest heating unit. This was located about 2.5 m away for 
the wardrobe drawer.
cCentral heating units of the three homes were on, with temperature set at 22.0°C (patient 1 and 4, January) or 21.5°C (patient 2, February). Central heating unit at home of patient 
no. 2 was on in March, and it was set at 21.5°C.
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inappropriate storage of l-T4 tablets and refractory hypothy-
roidism was supported by multiple measurements of serum 
TSH with highly statistically differences compared with the cor-
responding measurements under conditions of proper storage. 
Additional support comes from differences in temperatures in 
the microenvironment associated with inappropriate storage and 
temperatures associated with appropriate storage. One limitation 
of our study is not having measured FT4 by high-performance 
liquid chromatography (HPLC) in both improperly stored and 
properly stored T4 tablets. A second limitation is not having 
performed an oral acute loading test with l-T4 for the purpose of 
excluding pseudomalabsorption. A third limitation is not having 
tested patients for possible gene polymorphisms that impact on 
thyroid function tests, though existence of such polymorphisms 
seems unlikely (see below). Also taking into account the relative 
high frequency in the population and the possibility of persis-
tent serum TSH elevation upon standard replacement doses of 
projection can be made. For instance, with an estimated 15 mil-
lion Americans having hypothyroidism, approximately 150,000 
of them would have refractory hypothyroidism that could be due 
to improper storage of l-T4. If their refractory hypothyroidism is 
managed by progressively increasing the daily dose of l-T4 and 
if two TSH tests at a cost of $ 50 each are requested to monitor 
serum TSH, this practice would result in almost $ 8 million excess 
costs. However, the real rate of refractory hypothyroidism due 
to improper storage of l-T4 tablets could be higher than 1% of 
the total hypothyroid patients, because the common strategy 
of increasing the daily dose of l-T4 could obtain normalization 
of serum TSH.
The strength of the study is to have collected a series of 
patients with refractory hypothyroidism that could be attributed 
to precisely described circumstances in which one or more 
of three environmental factors were operating: temperature, 
light, and humidity. Another strength is that the link between 
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l-T4, one such polymorphism is the Ala92Thr variant of type 2 
deiodinase (23).
Thus, it is extremely unlikely that our adult or elderly 
patients with biochemical (elevated TPOAb and/or TgAb 
levels) and ultrasound features of thyroiditis had any genetic 
defect (24), e.g., monoallelic mutations in the TSH receptor 
(TSHR) gene, causing TSH-resistance and, consequently, 
refractory hypothyroidism. Indeed, monoallelic inactivating 
mutations of TSHR are associated with normal or hypoplasic 
thyroid, which is in contrast with the enlarged thyroid glands 
detected by US in all our patients. Nonetheless, the thyroidec-
tomized patient was entirely euthyroid prior to thyroidectomy 
(data not shown). Finally, upon evaluating the past history of 
patients with Hashimoto’s thyroiditis, we found that four of 
them had performed thyroid function some years earlier. These 
tests were performed when one consanguineous relative had 
developed Hashimotos’ thyroiditis-related hypothyroidism, 
so they wanted to make sure they were euthyroid and thyroid 
autoantibody negative. While they were indeed euthyroid, the 
four patients had elevated levels of TPOAb and/or TgAb (data 
not shown).
Recently, Van Wilder and co-workers have reported three 
patients presenting with persistent clinical and biochemical signs 
of hypothyroidism despite replacement therapy with high doses 
of levothyroxine (25). Although these three patients denied non-
compliance, a peroral 1,000 mcg l-T4 challenge test was positive 
in all cases, confirming the suspicion of pseudomalabsorption. 
Daily ingestion of the l-T4 tablets was confirmed by relatives 
and/or caregivers living with the patients, suggesting the absence 
of non-compliance as a possibility to explain hypothyroidism in 
these eight cases.
Another limitation of the present study is that, for humidity, 
microenvironment indicators were not provided.
CoNCLUDING ReMaRKs
Some hypothyroid patients use to store l-T4 tablets impro perly, 
and this habit causes failure of serum TSH to be normalized. 
Indeed, when these patients are instructed on the correct storage 
of l-T4 tablets, serum TSH concentrations normalize. Immediate 
recognition of l-T4 inappropriate storage avoids mismanage-
ment with increasing daily dose and frequent checks of hormone 
levels, and also avoids management of patients with unnecessary 
work-up when patients are referred to specialists. Thus, upon 
prescription of l-T4 tablets, patients need to be instructed on 
proper modalities of either ingestion or storage.
etHICs stateMeNt
This study was carried out with written informed consent from 
all subjects. All subjects gave written informed consent in accord-
ance with the declaration of Helsinki. Because patients recruited 
in the study underwent the regular work-up of hypothyroid 
subjects and were not submitted to life-risk procedures, the study 
protocol was not submitted to the Ethical Committed of the 
authors’ Institutions.
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